115 related articles for article (PubMed ID: 12490276)
1. Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation.
Herman J; Vandenberghe P; van den Heuvel I; Van Cleemput J; Winnepenninckx V; Van Damme-Lombaerts R
J Heart Lung Transplant; 2002 Dec; 21(12):1304-9. PubMed ID: 12490276
[TBL] [Abstract][Full Text] [Related]
2. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
Zilz ND; Olson LJ; McGregor CG
J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
[TBL] [Abstract][Full Text] [Related]
3. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.
Zhu K; Chen J; Chen S
Hematology; 2005 Oct; 10(5):365-70. PubMed ID: 16273722
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
[TBL] [Abstract][Full Text] [Related]
7. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R
Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216
[TBL] [Abstract][Full Text] [Related]
10. Favorable outcome of Epstein-Barr virus-associated B-cell lymphoproliferative disorder complicated by immunoglobulin G4-related disease treated with rituximab-based therapy: a case report.
Ueda K; Ikeda K; Ogawa K; Sukegawa M; Sano T; Kimura S; Suzuki O; Hashimoto Y; Takeishi Y
J Med Case Rep; 2016 Aug; 10(1):236. PubMed ID: 27557810
[TBL] [Abstract][Full Text] [Related]
11. Late donor cardiectomy after paediatric heterotopic cardiac transplantation.
Tsang V; Yacoub M; Sridharan S; Burch M; Radley-Smith R; Khaghani A; Savoldo B; Amrolia PJ
Lancet; 2009 Aug; 374(9687):387-92. PubMed ID: 19604574
[TBL] [Abstract][Full Text] [Related]
12. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.
Faye A; Quartier P; Reguerre Y; Lutz P; Carret AS; Dehée A; Rohrlich P; Peuchmaur M; Matthieu-Boué A; Fischer A; Vilmer E
Br J Haematol; 2001 Oct; 115(1):112-8. PubMed ID: 11722420
[TBL] [Abstract][Full Text] [Related]
13. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.
Verschuuren EA; Stevens SJ; van Imhoff GW; Middeldorp JM; de Boer C; Koëter G; The TH; van Der Bij W
Transplantation; 2002 Jan; 73(1):100-4. PubMed ID: 11792987
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders presented as interstitial pneumonia; successful recovery with rituximab.
Kunitomi A; Arima N; Ishikawa T
Haematologica; 2007 Apr; 92(4):e49-52. PubMed ID: 17562592
[TBL] [Abstract][Full Text] [Related]
15. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
[TBL] [Abstract][Full Text] [Related]
16. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte data in Epstein-Barr-virus induced post-transplant lymphoproliferative disorder treated by rituximab.
Entz-Werle N; Cojean N; Barats A; Eyer D; Munzer M; Uring-Lambert B; Falkenrodt A; Babin A; Lutz P
Pediatr Transplant; 2003 Aug; 7(4):277-81. PubMed ID: 12890005
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after a cord blood stem cell transplantation presenting with pulmonary nodules.
Shimasaki N; Mori T; Shimada H; Sugita M; Higuchi M; Mukai M; Morio T; Okamoto S
J Pediatr Hematol Oncol; 2004 Feb; 26(2):124-7. PubMed ID: 14767205
[TBL] [Abstract][Full Text] [Related]
19. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
20. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.
Gross TG; Orjuela MA; Perkins SL; Park JR; Lynch JC; Cairo MS; Smith LM; Hayashi RJ
Am J Transplant; 2012 Nov; 12(11):3069-75. PubMed ID: 22883417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
